Why OncoMed Pharmaceuticals, Inc. Shares Temporarily Spiked Higher
OncoMed Pharmaceuticals shares jump after the company releases early-stage data on two advanced pancreatic cancer drugs. Should investors be just as excited?
Stocks 2014: Investing For Growth - The Power And Protection Of High Compounding Earnings Growth - P
Stocks 2014: Investing For Growth - The Power And Protection Of High Compounding Earnings Growth - Part 2
Will Conservative Guidance Sink This Big Biotech in 2014?
Celgene recently slipped on weaker-than-expected guidance for 2014. Should investors buy the dip? Let’s compare Celgene to its big biotech peers Amgen, Biogen, and Gilead Sciences, to better understand its business and growth catalysts.
Was Celgene Corporation's Preview Really $2 Billion Worth of Disappointment?
Celgene disappointed investors with a Q4 earnings miss and lower-than-expected 2014 earnings projections. But was the news really that bad?